Denosumab: Are we making progress in treating cancer-related bone metastasis?

Community Oncology

Volumn 5, Issue 6, 2008, Pages 293-294

  Sehbai, Aasim ^a  

^a Tunnell Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OSTEOLYSIS; PATHOLOGIC FRACTURE; SHORT SURVEY;

EID: 46249103838     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70459-4     Document Type: Short Survey

References (2)

1. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437.
2. Sehbai A, Mirza A, Abraham J, et al. Osteonecrosis of the jaw associated with bisphosphonate therapy: tips for the practicing oncologist. Commun Oncol 2007;4:47-52.